Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
2023 UPDATE - Canadian Urological Association guideline: Management of cystic renal lesions Prior to original publication (March 2017), this guideline underwent review by the CUA Guidelines Committee, CUA members at large, and the CUA Executive Board. The 2023 updates were app roved by the CUA Guidelines Committee and CUA Executive Board.
Richard PO, Violette PD, Bhindi B, Breau RH, Gratton M, Jewett MAS, Kapoor A, Pouliot F, Leveridge M, So AI, Whelan TF, Rendon RA, Tanguay S, Finelli A. Richard PO, et al. Can Urol Assoc J. 2023 Jun;17(6):162-174. doi: 10.5489/cuaj.8389. Can Urol Assoc J. 2023. PMID: 37310905 Free PMC article. No abstract available.
Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement.
Lalani AA, Kapoor A, Basappa NS, Bhindi B, Bjarnason GA, Bosse D, Breau RH, Canil CM, Cardenas LM, Castonguay V, Chavez-Munoz C, Chu W, Dudani S, Graham J, Heng DYC, Kollmannsberger C, Lattouf JB, Morgan S, Reaume MN, Richard PO, Swaminath A, Tanguay S, Wood LA, Lavallée LT. Lalani AA, et al. Among authors: richard po. Can Urol Assoc J. 2023 May;17(5):E154-E163. doi: 10.5489/cuaj.8381. Can Urol Assoc J. 2023. PMID: 37185210 Free PMC article.
Reporting of costs and economic impacts in randomized trials of de-implementation interventions for low-value care: a systematic scoping review.
Falkenbach P, Raudasoja AJ, Vernooij RWM, Mustonen JMJ, Agarwal A, Aoki Y, Blanker MH, Cartwright R, Garcia-Perdomo HA, Kilpeläinen TP, Lainiala O, Lamberg T, Nevalainen OPO, Raittio E, Richard PO, Violette PD, Tikkinen KAO, Sipilä R, Turpeinen M, Komulainen J. Falkenbach P, et al. Among authors: richard po. Implement Sci. 2023 Aug 21;18(1):36. doi: 10.1186/s13012-023-01290-3. Implement Sci. 2023. PMID: 37605243 Free PMC article. Review.
Update on APPEAL, an International Randomized Controlled Trial Evaluating Ciprofloxacin Versus Placebo in Patients Undergoing Shockwave Lithotripsy for Urolithiasis.
Tikkinen KAO, Tornberg SV, Ruotsalainen J, Tadayon Najafabadi B, Horstia S, Hajebrahimi S, Mikkola A, Abdelkareem M, Richard PO, Bausch K, Parpia S, Guyatt GH, Violette PD; APPEAL Trial Investigators. Tikkinen KAO, et al. Among authors: richard po. Eur Urol Focus. 2024 Sep;10(5):697-699. doi: 10.1016/j.euf.2024.07.011. Epub 2024 Aug 6. Eur Urol Focus. 2024. PMID: 39112135
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
Pouliot F, Saad F, Rousseau E, Richard PO, Zamanian A, Probst S, Lévesque É, Castonguay V, Marcoux N, Lodde M, Juneau D, Hamilou Z, Lattouf JB, Buteau FA, Pavic M, Castilloux JF, Neveu B, Bouvet GF, Allard C, Tétu A, Guérin B, Beauregard JM; 3TMPO Investigators. Pouliot F, et al. Among authors: richard po. J Nucl Med. 2024 Nov 1;65(11):1710-1717. doi: 10.2967/jnumed.124.268020. J Nucl Med. 2024. PMID: 39327017 Free PMC article.
Length of hospital stay and procedure time after partial nephrectomy or percutaneous thermal ablation: A systematic review and meta-analysis.
Kandi M, Richard PO, Violette PD, Sreekanta A, Hanna S, Couban R, Daza J, Leong R, Faisal H, Tamilselvan D, Steen J, Tang WC, Guyatt G. Kandi M, et al. Among authors: richard po. Can Urol Assoc J. 2024 Oct 7. doi: 10.5489/cuaj.8906. Online ahead of print. Can Urol Assoc J. 2024. PMID: 39418494 Free article. Review.
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma.
Graham J, Ahmad AE, Basappa NS, Bernhard JC, Bhindi B, Bossé D, Breau RH, Canil CM, Castonguay V, Finelli A, Heng DYC, Inman BA, Kollmannsberger C, Lalani AA, Lavallée LT, Msaouel P, Prendeville S, Soleimani M, Tanguay S, Wood L, Richard PO. Graham J, et al. Among authors: richard po. Can Urol Assoc J. 2024 Nov;18(11):E371-E386. doi: 10.5489/cuaj.9041. Can Urol Assoc J. 2024. PMID: 39500366 Free PMC article. No abstract available.
Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer-Specific Mortality, and All-Cause Mortality.
Robert A, Mallick R, McIsaac DI, Lavallée LT, Bhindi B, Heng D, Wood LA, Rendon R, Tanguay S, Finelli A, Bansal RK, Lalani AK, Basappa N, Mannas MP, Nayak JG, Bjarnason GA, Lattouf JB, Pouliot F, Richard PO, Tajzler C, Breau RH. Robert A, et al. Among authors: richard po. J Urol. 2024 Dec 2:101097JU0000000000004348. doi: 10.1097/JU.0000000000004348. Online ahead of print. J Urol. 2024. PMID: 39622017
85 results